Učitavanje...
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
Two open‐label studies assessed the safety, tolerability, and pharmacokinetics of Oxbryta (voxelotor) in subjects with hepatic or renal impairment. Eight subjects with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m(2)) and 8 healthy age‐, sex‐, and body mass index...
Spremljeno u:
| Izdano u: | J Clin Pharmacol |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7984382/ https://ncbi.nlm.nih.gov/pubmed/33084052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1757 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|